Company / Cash & Equivalents
Cooper Companies (The) Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$110.6M
FY2025
5-year range
$95.9M / $138.2M
FY2021-FY2025
Trend
+2.8%
vs FY2024
Sector context
#106 of 148
Health Care
What the data says
At $111M, Cooper Companies (The)'s cash & equivalents ranks #106 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $78M in FY2019 to $138M in FY2023.
Based on SEC 10-K filings.
$111M in FY2025 with a 5-year CAGR of +4.4%.
Declined from $138M to $111M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +4.9%
- 5-Year CAGR
- +4.4%
- 10-Year CAGR
- -
Sector benchmark
#106 of 148 in Health CareTop 72% of 148This company $110.6M Sector average $1.2B
▼
-90.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.4%, indicating consistent growth.
- In FY2025, cash & equivalents increased 2.8% year-over-year.
- Ranks #106 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $110.6M | +2.8% |
| FY2024 | $107.6M | -22.1% |
| FY2023 | $138.2M | +44.1% |
| FY2022 | $95.9M | -17.3% |
| FY2021 | $115.9M | +30.2% |
| FY2020 | $89.0M | +14.5% |
| FY2019 | $77.7M | +0.0% |
| FY2018 | $77.7M | -22.9% |
| FY2017 | $100.8M | +0.0% |
| FY2016 | $100.8M | +514.6% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026